238 related articles for article (PubMed ID: 34703227)
1. Cetuximab-Modified Human Serum Albumin Nanoparticles Co-Loaded with Doxorubicin and MDR1 siRNA for the Treatment of Drug-Resistant Breast Tumors.
Yang X; Wang Y; Chen S; Zhang S; Cui C
Int J Nanomedicine; 2021; 16():7051-7069. PubMed ID: 34703227
[TBL] [Abstract][Full Text] [Related]
2. Preparation Optimization of Bovine Serum Albumin Nanoparticles and Its Application for siRNA Delivery.
Wang Y; Chen S; Yang X; Zhang S; Cui C
Drug Des Devel Ther; 2021; 15():1531-1547. PubMed ID: 33883877
[TBL] [Abstract][Full Text] [Related]
3. siRNA Targeting of MDR1 Reverses Multidrug Resistance in a Nude Mouse Model of Doxorubicin-resistant Human Hepatocellular Carcinoma.
Yang H; Ding R; Tong Z; Huang J; Shen L; Sun YU; Liao J; Yang Z; Hoffman RM; Wang C; Meng X
Anticancer Res; 2016 Jun; 36(6):2675-82. PubMed ID: 27272776
[TBL] [Abstract][Full Text] [Related]
4. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
[TBL] [Abstract][Full Text] [Related]
5. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery.
Gu J; Fang X; Hao J; Sha X
Biomaterials; 2015 Mar; 45():99-114. PubMed ID: 25662500
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin-Bound Albumin Nanoparticles Containing a TRAIL Protein for Targeted Treatment of Colon Cancer.
Thao le Q; Byeon HJ; Lee C; Lee S; Lee ES; Choi YW; Choi HG; Park ES; Lee KC; Youn YS
Pharm Res; 2016 Mar; 33(3):615-26. PubMed ID: 26526555
[TBL] [Abstract][Full Text] [Related]
7. Rational Design of Multifunctional Polymeric Nanoparticles Based on Poly(l-histidine) and d-α-Vitamin E Succinate for Reversing Tumor Multidrug Resistance.
Li Z; Chen Q; Qi Y; Liu Z; Hao T; Sun X; Qiao M; Ma X; Xu T; Zhao X; Yang C; Chen D
Biomacromolecules; 2018 Jul; 19(7):2595-2609. PubMed ID: 29618203
[TBL] [Abstract][Full Text] [Related]
8. Tumor-targeting pH/redox dual-responsive nanosystem epigenetically reverses cancer drug resistance by co-delivering doxorubicin and GCN5 siRNA.
Yuan Y; Liu J; Yu X; Liu X; Cheng Y; Zhou C; Li M; Shi L; Deng Y; Liu H; Wang G; Wang L; Wang Z
Acta Biomater; 2021 Nov; 135():556-566. PubMed ID: 34496281
[TBL] [Abstract][Full Text] [Related]
9. Indocyanine green/doxorubicin-encapsulated functionalized nanoparticles for effective combination therapy against human MDR breast cancer.
Chen HH; Lu IL; Liu TI; Tsai YC; Chiang WH; Lin SC; Chiu HC
Colloids Surf B Biointerfaces; 2019 May; 177():294-305. PubMed ID: 30771581
[TBL] [Abstract][Full Text] [Related]
10. EGFR Targeted Cetuximab-Valine-Citrulline (vc)-Doxorubicin Immunoconjugates- Loaded Bovine Serum Albumin (BSA) Nanoparticles for Colorectal Tumor Therapy.
Ye Z; Zhang Y; Liu Y; Liu Y; Tu J; Shen Y
Int J Nanomedicine; 2021; 16():2443-2459. PubMed ID: 33814909
[TBL] [Abstract][Full Text] [Related]
11. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
Wen ZM; Jie J; Zhang Y; Liu H; Peng LP
Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938
[TBL] [Abstract][Full Text] [Related]
12. Codelivery of doxorubicin and MDR1-siRNA by mesoporous silica nanoparticles-polymerpolyethylenimine to improve oral squamous carcinoma treatment.
Wang D; Xu X; Zhang K; Sun B; Wang L; Meng L; Liu Q; Zheng C; Yang B; Sun H
Int J Nanomedicine; 2018; 13():187-198. PubMed ID: 29343957
[TBL] [Abstract][Full Text] [Related]
13. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo.
Meng H; Mai WX; Zhang H; Xue M; Xia T; Lin S; Wang X; Zhao Y; Ji Z; Zink JI; Nel AE
ACS Nano; 2013 Feb; 7(2):994-1005. PubMed ID: 23289892
[TBL] [Abstract][Full Text] [Related]
14. Overcoming Multidrug Resistance by Codelivery of MDR1-Targeting siRNA and Doxorubicin Using EphA10-Mediated pH-Sensitive Lipoplexes: In Vitro and In Vivo Evaluation.
Zhang J; Du Z; Pan S; Shi M; Li J; Yang C; Hu H; Qiao M; Chen D; Zhao X
ACS Appl Mater Interfaces; 2018 Jun; 10(25):21590-21600. PubMed ID: 29798663
[TBL] [Abstract][Full Text] [Related]
15. Star polyester-based folate acid-targeting nanoparticles for doxorubicin and curcumin co-delivery to combat multidrug-resistant breast cancer.
Guo F; Yu N; Jiao Y; Hong W; Zhou K; Ji X; Yuan H; Wang H; Li A; Wang G; Yang G
Drug Deliv; 2021 Dec; 28(1):1709-1721. PubMed ID: 34463174
[TBL] [Abstract][Full Text] [Related]
16. Co-delivery of DOX and PDTC by pH-sensitive nanoparticles to overcome multidrug resistance in breast cancer.
Cheng X; Li D; Sun M; He L; Zheng Y; Wang X; Tang R
Colloids Surf B Biointerfaces; 2019 Sep; 181():185-197. PubMed ID: 31132609
[TBL] [Abstract][Full Text] [Related]
17. Enhanced therapeutic effect of Adriamycin on multidrug resistant breast cancer by the ABCG2-siRNA loaded polymeric nanoparticles assisted with ultrasound.
Bai M; Shen M; Teng Y; Sun Y; Li F; Zhang X; Xu Y; Duan Y; Du L
Oncotarget; 2015 Dec; 6(41):43779-90. PubMed ID: 26575421
[TBL] [Abstract][Full Text] [Related]
18. Low-density lipoprotein-coupled N-succinyl chitosan nanoparticles co-delivering siRNA and doxorubicin for hepatocyte-targeted therapy.
Zhu QL; Zhou Y; Guan M; Zhou XF; Yang SD; Liu Y; Chen WL; Zhang CG; Yuan ZQ; Liu C; Zhu AJ; Zhang XN
Biomaterials; 2014 Jul; 35(22):5965-76. PubMed ID: 24768047
[TBL] [Abstract][Full Text] [Related]
19. [Reversing multidrug resistance in breast cancer cell line MCF-7/ADR by small interfering RNA].
Li CB; Zhang F; Shi YR; Wei XY; Yang Y; Niu RF
Ai Zheng; 2004 Dec; 23(12):1605-10. PubMed ID: 15601546
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin and siRNA Codelivery via Chitosan-Coated pH-Responsive Mixed Micellar Polyplexes for Enhanced Cancer Therapy in Multidrug-Resistant Tumors.
Butt AM; Amin MC; Katas H; Abdul Murad NA; Jamal R; Kesharwani P
Mol Pharm; 2016 Dec; 13(12):4179-4190. PubMed ID: 27934479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
